Clinical trials show oral glutathione at 500mg doses reduces melanin index when taken consistently for 8-12 weeks
This represents the best-quality clinical evidence for DSIP, though the sample size was small Multi-species animal data -- DSIP has demonstrated sleep-promoting effects in rabbits, mice, rats, cats, and humans Stress modulation -- DSIP suppresses stress-induced cortisol and ACTH rises, potentially relevant for stress-related insomnia Opioid and alcohol withdrawal -- small studies explored DSIP as an adjunct in withdrawal management 2024 fusion peptide study -- published in Frontiers in Pharmacology, research on DSIP-BBB fusion peptides in insomnia mouse models represents renewed interest in DSIP Important limitations of DSIP's clinical evidence: Most studies are from the 1980s-1990s, conducted before modern polysomnography and sleep study methodology were standardized Sample sizes are consistently small Results are inconsistent across studies -- some show clear sleep effects while others do not No large-scale, placebo-controlled RCTs have been conducted Publication bias (positive results more likely published) may inflate the apparent evidence Side Effects Comparison# Cortistatin Side Effects# No human safety data exists
These results demonstrated the additive benefits of targeting both amylin and GLP-1 pathways for glycemic control and weight management in type 2 diabetes and supported advancement to Phase 3 development
Cyclodextrin-based supramolecular polymers
Recent advances in single-cell and spatial transcriptomic technologies (see Sidebar 10 ) are transforming our understanding of the TME by helping map the cellular and molecular interactions that occur within and around tumors
Peptides, glutaryl-CoA or succinyl-CoA were subsequently diluted to 2.5 mM in assay buffer (50 mM TrisHCl pH 7.4, 100 mM NaCl)
